Adar Poonawalla: the vaccine prince who will save the world
Adar Poonawalla, the chief of the world’s biggest vaccine manufacturer by volume, has an ambitious plan to rescue us all from Covid-19. The future for his dynasty looks bright, says Jane Lewis.
![Adar Poonawalla](https://cdn.mos.cms.futurecdn.net/jJc5FdWGx85c9NdYgGACgY-415-80.jpg)
If the world manages to escape the clutches of Covid-19 this year, it may be largely down to the efforts of Adar Poonawalla – the Indian tycoon known as “the vaccine prince”, says The Times. Poonawalla’s company, Serum Institute of India (SII), is “comfortably the biggest vaccine manufacturer by volume in the world”: some two-thirds of all the children on the planet have been vaccinated with one or more of its products. The company makes 1.5 billion doses of vaccines annually against diseases such as polio, diphtheria and hepatitis B.
Now Poonawalla, 39, “has an ambitious plan” to supply the Oxford/AstraZeneca coronavirus vaccine to half the planet by this time next year. And he plans to do so at $3 a dose, “which barely covers costs”. When the pandemic set in, he says, “I decided to go all out” – immediately embarking on a dramatic expansion of manufacturing facilities funded by £270m of his company’s money and another £3m from the Bill and Melinda Gates Foundation. The family has cash to spare. According to Forbes, his father, Cyrus Poonawalla, who founded the company in 1966, is worth $11.5bn, making him India’s sixth richest man last year.
Indeed, Poonawalla senior (“the vaccine king”) has almost doubled his wealth during the pandemic, says Business Today (India), thanks to partnerships with global pharmaceutical majors. Poonawalla junior is clear that his primary motivation is not to make money, but to save lives. Whatever the case, he has been lauded across Asia as one of the world’s chief “virus busters”, says The Economic Times of India.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
![https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748-320-80.jpg)
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
A life of glamour
The Poonawallas – so called because of their base in the city of Pune (known as Poona during the British Raj) – are “a fixture of India’s business aristocracy”, noted the FT in 2014. The family is famous for its stable of racehorses, its stud farm, and one of the country’s most expensive sports-car collections. In 2015 the clan bought a sprawling seaside mansion in Mumbai for $113m in “the most expensive residential property deal in India’s history”. Adar Poonawalla was educated in Britain and enjoys an old-fashioned life of glamour – owning paintings by Picasso, Dali, Rembrandt and Rubens, spending holidays on the French Riviera, attending grand prix and calling the Prince of Wales “a close and very dear friend”. His private office, notes The Times, is “a disused Airbus A320”, which he has lavishly refurbished, complete with boardroom and bedroom.
The family’s journey into vaccines happened almost by chance, says Business Insider. Although hailing from a family of wealthy landowners, Cyrus Poonawalla inherited just 40 acres and knew he had to go into business. It was “a chance meeting with a veterinarian” who worked at his stud farm that triggered an idea to produce vaccines. The timing was propitious, says The Times. When he set up the Serum Institute in 1966, “lots of new vaccines were coming on stream”, but most were imported and far too pricey for most of the country’s population – so the business took off rapidly. It got another boost when Adar Poonawalla joined in 2001 and started developing an international market – cutting the price of vaccines by producing them in huge quantities and focusing on developing countries that the pharma giants ignored.
The future for the dynasty looks bright. Once “a niche industry”, vaccine manufacturing has found a new status due to Covid-19 and the growing threat of future global pandemics. The modern world, says Poonawalla, is “a melting pot…just waiting to churn out more of these kinds of terrible viruses”. He thinks we were “lucky” with Covid-19. “Can you imagine if ebola were as infectious as coronavirus?”
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Jane writes profiles for MoneyWeek and is city editor of The Week. A former British Society of Magazine Editors editor of the year, she cut her teeth in journalism editing The Daily Telegraph’s Letters page and writing gossip for the London Evening Standard – while contributing to a kaleidoscopic range of business magazines including Personnel Today, Edge, Microscope, Computing, PC Business World, and Business & Finance.
She has edited corporate publications for accountants BDO, business psychologists YSC Consulting, and the law firm Stephenson Harwood – also enjoying a stint as a researcher for the due diligence department of a global risk advisory firm.
Her sole book to date, Stay or Go? (2016), rehearsed the arguments on both sides of the EU referendum.
She lives in north London, has a degree in modern history from Trinity College, Oxford, and is currently learning to play the drums.
-
Skipton launches a retirement bond with monthly income – is it any good?
The building society has launched a new three-year fixed-rate bond for those aged 66 and over. Can it boost your retirement income?
By Katie Williams Published
-
Pensions: 140,000 pensioners to be hit by surprise tax demand
Tens of thousands of pensioners will be written to over the summer because their pensions have gone above the frozen income tax thresholds
By Chris Newlands Published
-
CrowdStrike IT outage: a global meltdown
Millions were affected by the CrowdStrike IT outage recently, which grounded flights and took the news off the air. Was this just a hiccup or a warning of much worse to come?
By Simon Wilson Published
-
Revolut founder Nik Storonsky cashes in – what's next for the fintech billionaire?
Nik Storonsky has shaken up the banking industry with Revolut. He is now preparing a new project that could do the same to the venture capital sector
By Jane Lewis Published
-
Is local production making a comeback?
Companies return production closer to home and shorten their supply chains due to the pandemic and geopolitical turmoil. How should investors react?
By Dr Matthew Partridge Published
-
French election: an unexpected win for the left-wing
The snap French election delivered a stalemate. What does this mean for the country's stability?
By Dr Matthew Partridge Published
-
Rachel Reeves: Britain’s new iron chancellor
Rachel Reeves enters No. 11 Downing Street with a determination to keep a tight grip on the purse strings. She has the makings of a chancellor of consequence.
By Jane Lewis Published
-
Amazon turns 30 – what will the next decade bring?
Amazon started life as an online bookseller operating out of a garage in Seattle. What does its future hold?
By Simon Wilson Published
-
Margot Robbie launches new gin brand
Margot Robbie is an actress, producer, investor and now a liquor baron with her new gin brand
By Jane Lewis Published
-
Return of Larry Ellison: the god of Silicon Valley
Larry Ellison, the founder of Oracle, was a pioneer of the US tech scene in the 1970s. The AI boom has given him a new lease of life.
By Jane Lewis Published